Related Experiment Videos
Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children
Insights
Graft-versus-host disease (GVHD) prophylaxis and treatment in pediatric allogeneic stem cell transplantation (SCT) varies widely. This study assessed current practices to guide the development of a uniform GVHD management policy for children.
Area of Science:
- Pediatric Hematology/Oncology
- Immunology
- Transplantation Medicine
Background:
- Significant variability exists in current pediatric approaches to graft-versus-host disease (GVHD) prophylaxis and treatment following allogeneic stem cell transplantation (SCT).
- Lack of standardized protocols may impact patient outcomes in this vulnerable population.
Purpose of the Study:
- To evaluate existing local standards for GVHD prevention and treatment in children undergoing allogeneic SCT.
- To identify areas requiring further investigation to establish a uniform GVHD management policy.
Main Methods:
- Conducted conferences with members of the EBMT Working Party Paediatric Diseases and the International BFM Study Group—Subcommittee Bone Marrow Transplantation.
- Assessed current and investigational practices in pediatric GVHD management.
- Identified knowledge gaps and areas for future research.
Main Results:
- Cyclosporine A (CsA) +/- methotrexate (MTX) is the preferred GVHD prophylaxis in most pediatric centers; folinic acid is considered for MTX-related side effects.
- First-line treatment for acute GVHD typically involves prednisolone and CsA; refractory cases increasingly use ATG, mycophenolate mofetil, or tacrolimus.
- Chronic GVHD management commonly uses prednisolone and CsA combinations, with extracorporeal photopheresis, PUVA, and thalidomide for severe cases.
Conclusions:
- Current GVHD prophylaxis and treatment strategies in pediatric SCT are diverse.
- Further research and consensus-building are necessary to develop standardized, evidence-based guidelines for pediatric GVHD management.
Abstract:
Great variations exist in the prophylaxis and treatment of GVHD in children undergoing allogeneic stem cell transplantation (SCT). The EBMT Working Party Paediatric Diseases (EBMT-WP PD) and the International BFM Study Group--Subcommittee Bone Marrow Transplantation (IBFM-SG), aimed at evaluating current local standards in the prevention and treatment of GVHD and steps which can be taken to achieve a uniform policy for the individual methods. Several conferences with their members assessed practices which are mainly applied or under investigation in children and identified where additional information is needed. For prevention of GVHD, the majority of the paediatric centres prefer CsA +/- MTX. Addition of folinic acid to MTX was considered for reduction of side-effects. During treatment of acute GVHD most centres administer prednisolone and whole blood level-adjusted CsA as medications of first choice. In cases of poor or no response to this therapy, additional immunosuppressive agents such as ATG, mycophenolate-mofetile and tacrolimus are being increasingly used. The treatment of chronic GVHD usually consists of various combinations of prednisolone and CsA. In severe cases, extracorporeal photopheresis, psoralene-UVA (PUVA) and thalidomide are administered.